Document is current
Any future updates will be listed below
-
Authors
Peng, Xiyu https://orcid.org/0000-0003-4232-0910
Smithy, James W.
Yosofvand, Mohammad
Kostrzewa, Caroline E.
Bleile, MaryLena
Ehrich, Fiona D. https://orcid.org/0000-0002-2245-9352
Lee, Jasme
Postow, Michael A. https://orcid.org/0000-0002-3367-7961
Callahan, Margaret K.
Panageas, Katherine S.
Shen, Ronglai https://orcid.org/0000-0001-9694-584X
-
Funding
Funding for this research was provided by:
Society of Memorial Sloan Kettering
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, R01 CA276286, P30 CA008748, P30 CA008748, R01 CA276286, P30 CA008748, R01 CA276286, P30 CA008748, R01 CA276286)
V Foundation for Cancer Research
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 3 July 2025
First Online: 18 July 2025
Competing interests
: J.W.S.: Research funding—IO Biotech (Inst), Regeneron (Inst), Daiichi Sankyo (Inst); Consulting or advisory role—IO Biotech, Iovance, Bristol Myers Squibb, Daiichi Sankyo; Travel—Immatics; M.A.P.: Consulting or Advisory Role—Bristol-Myers Squibb; Cancer Expert Now; Chugai Pharma; Eisai; Erasca, Inc; Intellisphere; Merck; MJH Associates; Nektar; Novartis; Pfizer; WebMD; Research Funding—Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst); K.S.P. Stock ownership in 23 and Me, Vincerx, Eyepoint, and Kyverna; C.E.K.: Stock ownership in Johnson & Johnson; M.K.C.: BMS—Research support (Inst), advisory role/consulting; Medimmune—advisory role/consulting; Immunocore—advisory role/consulting; Merus—family member employee; M.B.: Regeneron—collaborator; Sanofi—direct contractor; X.P., J.L., M.Y., R.S., and F.D.E.: No disclosures;
